Trials / Completed
CompletedNCT05419375
Screening Study for Participants With Malignant Tumors
Master Screening Study to Determine Biomarker Status and Potential Trial Eligibility for Patients With Malignant Tumors
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 470 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study objective is to determine the biomarker status of a participant's tumor tissue and use that status to determine eligibility for a linked Roche clinical trial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Screening platform | The screening platform will be used to determine biomarker eligibility for a linked Roche study based on tissue-based testing. |
Timeline
- Start date
- 2022-07-22
- Primary completion
- 2025-09-03
- Completion
- 2025-09-03
- First posted
- 2022-06-15
- Last updated
- 2026-02-03
Locations
79 sites across 26 countries: United States, Australia, Brazil, Canada, Chile, Colombia, Costa Rica, France, Germany, Hong Kong, India, Israel, Italy, Japan, Mexico, Netherlands, New Zealand, Poland, Serbia, Singapore, South Korea, Spain, Taiwan, Thailand, Turkey (Türkiye), United Kingdom
Source: ClinicalTrials.gov record NCT05419375. Inclusion in this directory is not an endorsement.